Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00253552 · ClinicalTrials.gov registry record · NA
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
A NA study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT00253552 is a NA study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 4 participants.
The verdict
NCT00253552, a NA study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving colony-stimulating factors, such as G-CSF, to the donor helps the stem cells move from the bone marrow to the blood so they can be collected and stored. PURPOSE: This clinical trial is studying how well a G-CSF-treated donor bone marrow transplant works in treating patients with hematologic cancer or noncancer.
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG busulfan
- DRUG cyclosporine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00253552
The ClinicalTrials.gov registry entry for NCT00253552 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00253552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00253552 about?
NCT00253552 is a clinical study titled "G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders". RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the pat...
What is the current status of trial NCT00253552?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2004-05. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00253552?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), busulfan (DRUG), cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00253552?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.